HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Profit from the Pros – Zacks Free Email Newsletter
Our free email newsletter is filled with timely stock picks and market commentary. Sign up for free. Already on board? Check out the archive.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


MNKD: Mannkind Cp - Stock News Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Company News |  Zacks Commentary
MANNKIND CP (NASD)
MNKD 6.95 0.07 (1.02%) Vol.  473,675 16.00 CST

Nov 17, 2009 Conference Calls Today: 2-2:10 P.M. EDT
Nov 11, 2009 MannKind Down 7.8% Since SmarTrend's Sell Recommendation
Nov 04, 2009 MannKind Down 19.1% Since SmarTrend's Sell Recommendation
Nov 04, 2009 Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
Nov 02, 2009 CORRECTING and REPLACING MannKind Corporation Reports Third Quarter Financial Results
Nov 02, 2009 MannKind to Present at Upcoming Conferences
Nov 02, 2009 MannKind Corporation Reports Third Quarter Financial Results
Oct 29, 2009 Studies Show Early Promise of MannKind's Cancer Immunotherapy Program in Melanoma, Prostate Cancer and Other Solid Malignancies
Oct 27, 2009 Trading Outlook for Generex Biotechnologies Corp. Issued by InvestorSoup.com
Oct 27, 2009 MannKind Down 24.6% Since SmarTrend's Sell Recommendation
Oct 26, 2009 MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 2, 2009
Oct 20, 2009 MannKind Down 24.2% Since SmarTrend's Sell Recommendation
Oct 12, 2009 MannKind Down 9.7% Since SmarTrend's Sell Recommendation
Oct 08, 2009 BUYINS.NET Issues Short Sale Report On MannKind
Oct 02, 2009 AFRESA(R) Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function in Patients over Four Years of Treatment
 
ZACKS COMMENTARY FOR MNKD
Nov 03, 2009 Zacks Blog: MannKind Beats, Awaiting FDA
Oct 07, 2009 Zacks Blog: MannKind Slides on News
Sep 10, 2009 Zacks Equity Research: Report for MNKD
Jun 26, 2009 Zacks Blog: Will MannKind Bounce Back?
Jun 19, 2009 Zacks Blog: Aradigm’s Pipeline Undervalued
Jun 08, 2009 Zacks Blog: Zacks Analyst Blog Highlights: MannKind, Pfizer, Inc., Novo Nordisk, Eli Lilly and Alkermes Pharmaceuticals.
Jun 05, 2009 Zacks Blog: Raising MannKind to Hold
Feb 19, 2009 Zacks Blog: MannKind Remains in Peril
Jan 23, 2009 Zacks Blog: Biotech Industry
Dec 05, 2008 Zacks Analyst Interviews: Biotechnology Industry
Dec 04, 2008 Zacks Blog: Biotechnology Industry

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research